Superparamagnetic iron oxide – Loaded poly (lactic acid)-d-α-tocopherol polyethylene glycol 1000 succinate copolymer nanoparticles as MRI contrast agent
Introduction
Versatility in the use of supraparamagnetic iron oxide nanocrystals (SPIOs or IOs) has gained tremendous importance in the field of biomedical application. In cancer research, for example, IOs have been used for molecular imaging, tumor imaging, cancer hyperthermia therapy, and other techniques [1], [2], [3], [4]. IOs have been extensively investigated as a contrast agent for MRI, which are easily assimilated by the human body [5], [6], [7]. IOs are primarily used in MRI as liver signal erasers since they create a reduction in signal intensity in the reticuloendothelial tissues, in which they are greatly concentrated and thus result in greater T2 shortening, to produce more conspicuous area of liver not containing the reticuloendothelial tissues. However, long term retention of IOs in liver is a concern for the side effects of IOs imaging agent [8]. Several other side effects are also associated with administering of the IOs, which may create clinical complications [9].
Such problems could be addressed by two strategies. One is by coating of the IOs core and another is by formulating of the IOs in nanoparticles (NPs) of biodegradable polymers. Various coating techniques have been suggested to provide IOs with functionality of desired surface properties. For instance, thermally sensitive coatings provide the IOs with dual functionality for treatment of cancer by hyperthermia and through a release of the entrapped anti-cancer agent [10]. In another study, IOs with their surface coated with PEG and further linked to biotin or neutravidin along with a peptide enabled detection of specific cancer type that produces a proteolytic enzyme which enabled the peptide blocked biotin and neutravidin to self assemble and thus influences the T2 relaxivity in MRI. Such a coating strategy thus enables detection of the tumor as well as specification of the tumor type [11]. Moreover, coating IOs by hydrophilic or amphiphilic biodegradable polymer provides them with other functionality such as biocompatibility and long circulation in plasma.
Formulation of the IOs in nanoparticles (NPs) can be realized by using various FDA-approved biodegradable polymers such as poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) and various novel biodegradable copolymers such as poly(lactic acid)-poly(ethylene glycol) (PLEA) copolymer and poly(lactic acid)-d-α-tocopherol polyethylene glycol 1000 succinate (PLA–TPGS) copolymer [12], [13], [28]. Encapsulation by using preformed polymer can be done by several methods such as the micro/nanoemulsion method [14], [15], the nanoprecipitation method [16], [17] and the micelle formation [18], [19], [20]. Emulsion polymerization makes use of monomers that polymerize over the encapsulant, which is stabilized by using a surfactant [21], [22], [23], which is of great concern due to the presence of certain chemical precursors that were not removed and could have some cytotoxic effect [24]. The solvent displacement technique was used in the preparation of nanocapsules [24]. The nanocapsules were formed when the non-solvent replaces the solvent in the presence of a surfactant followed by deposition of the preformed polymer at the interface. The encapsulant was remained in an oily phase within the polymer layer. This process has been extended to the formation of nanospheres without the surfactant [16] and it has been gaining increasing importance over time for preparing nanoparticles. Various parameter optimization of this method has been done. For instance, it was suggested that the diffusion of the solvent into the non-solvent results in the phase transformation of the polymer and thus in the formation of the nanoparticles [25]. It was also shown how the nanoparticles formation could be affected by changing the concentration of the polymer in the organic phase or the concentration of the surfactant in the aqueous phase, which may influence the size of the formed nanoparticles [26]. Other research in the nanoprecipitation method included the choice of the solvent [27]. It was suggested that the solubility parameter of the solvent and the non-solvent system strongly influence the particle formation, in which the particle size was usually used as the primary criteria for optimization in the literature.
In the present research, we developed a strategy to formulate IOs in the NPs of PLA–TPGS copolymer, for enhanced MRI of higher image contrast and less system side effects. The amphiphilic nature and enhanced biocompatibility of this copolymer make it promising for nanoparticle delivery of diagnostic and therapeutic agents [28], [29]. We have exploited the different treatment between drug and the IOs in the nanoparticle encapsulation process. A crystalline drug after encapsulation could become in an amorphous state, resulting in approved solubility [30], [31], [32], whereas the IOs do not undergo a phase transition after encapsulation process. Rather these nanoparticles get entrapped within the polymeric matrix and retain their crystalline state. Thus diffusion of the solvent into the polymeric matrix plays a key role during the preparation of the nanoparticle encapsulation.
Two commonly used methods for polymeric nanoparticle preparation, namely the single emulsion method and the nanoprecipitation method, are employed in this research for the nanoparticle preparation in close comparison with optimization of the various synthesis parameters such as the emulsifier concentration in the aqueous phase, solvent/non-solvent ratio, loading of IOs/drug and more. The effect of synthesis parameters on the size and size distribution of the polymeric nanoparticles and the distribution of IOs within the polymeric matrix were studied by laser light scattering and transmission electron microscopy (TEM). The optimally synthesized nanoparticles were further investigated for in vitro cytotoxicity and cellular uptake of the IOs-loaded nanoparticles in close comparison with the commercial Resovist®. Due to their desired particles size and their long half-life in the plasma, the IOs-loaded PLA–TPGS nanoparticles should have the property to accumulate in regions of leaky and high permeable vasculature and lymphatic vessels such as those in tumor, which is also referred to as the enhanced permeability and retention (EPR). The nanoparticle formulation of IOs can thus be exploited for passively targeted delivery of the imaging agent for clinical MRI with better contrast and less side effects [33].
Section snippets
Materials
Lactide (3,6-dimethyl-1,4-dioxane-2,5-dione, C6H8O4) was purchased from Aldrich, which was recrystallized twice from ethyl acetate before use. Vitamin E TPGS (d-α-tocopherol polyethylene glycol 1000 succinate, C33O5H54(CH2CH2O)23) was from Eastman chemical company (USA), which was freeze dried for two days before use. Stannous octoate (Sn(OOCC7H15)2) was purchased from Sigma and was used as 1% distilled toluene solution. Millipore water was prepared by a Milli-Q Plus System (Millipore
Synthesis of PLA–TPGS copolymer
PLA–TPGS (with a ratio 90:10 of PLA:TPGS) was successfully synthesized by ring opening polymerization. The polymer was characterized using FTIR and 1H NMR as shown in Fig. 1. The carbonyl band shift from 1730 cm−1 for TPGS to 1755 cm−1 for PLA–TPGS polymer and also the CH stretching at 2945 cm−1 for PLA to at 2880 cm−1 for that for TPGS can be observed from the FTIR spectra (Fig. 1A). The successful synthesis of PLA–TPGS copolymer was further verified by 1H NMR for the presence of CH proton
Conclusion
The IOs-loaded PLA–TPGS NPs (IOs-PNPs) prepared by the single emulsion method and the nanoprecipitation method at the various process parameters, especially the IOs loading level in the NPs and the solvent/non-solvent ratio used in the process, were characterized for their physicochemical and supraparamagnetic properties for an optional formulation using nanoprecipitation method. We found that the IOs-PNPs prepared by the nanoprecipitation method at the 4:15 solvent/non-solvent ratio and 2% IOs
Acknowledgement
The authors are thankful for the financial support from the NUS FOE Grant R-279-000-226-112 and NanoCore Grant R-279-000-284-646 as well as A Singapore A*STAR SBIC (Singapore Bioimaging Consortium, Agency of Science Technology and Research).
References (38)
- et al.
Assessing responses to cancer therapy using molecular imaging
Biochem Biophys Acta
(2006) - et al.
Long-circulating iron oxides for MR imaging
Adv Drug Deliv Rev
(1995) - et al.
Biomedical nanoparticle carriers with combined thermal and magnetic responses
Nano Today
(2009) - et al.
A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: micelles, nanospheres, nanocapsules and polymerosomes
Eur J Pharm Biopharm
(2007) - et al.
Magnetic enhancement of iron oxide nanoparticles encapsulated with poly(d,l-latide-co-glycolide)
Colloids Surf A
(2005) - et al.
Formulation of functionalized PLGA–PEG nanoparticles for in vivo targeted drug delivery
Biomaterials
(2007) - et al.
Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging
Biomaterials
(2009) Superparamagnetic latex via inverse emulsion polymerization
J Colloid Interface Sci
(2001)- et al.
Magnetic poly(glycidyl methacrylate) microspheres containing maghemite prepared by emulsion polymerization
J Magn Magn Mater
(2006) - et al.
Nanocapsule formation by interfacial polymer deposition following solvent displacement
Int J Pharm
(1989)
Influence of stabilizing agents and preparative variables on the formation of poly(d,l-lactic acid) nanoparticles by an emulsification–diffusion technique
Int J Pharm
Nanoparticles of poly(lactide)/vitamin E TPGS copolymer for cancer chemotherapy: synthesis, formulation, characterization and in vitro drug release
Biomaterials
In vitro and in vivo evaluation of methoxy polyethylene glycol–polylactide (mPEG–PLA) nanoparticles for small-molecule drug chemotherapy
Biomaterials
A novel controlled release formulation for anticancer drug paclitaxel (Taxols): PLGA nanoparticles containing vitamin E TPGS
J Control Release
Synthesis of magnetite nanoparticles via a solvent-free thermal decomposition route
J Magn Magn Mater
Synthesis of iron oxide nanoparticles under oxidizing environment and their stabilization in aqueous and non-aqueous media
J Magn Magn Mater
Iron oxide MR contrast agents for molecular and cellular imaging
NMR Biomed
Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model
Radiology
Inductive heating of ferrimagnetic particles and magnetic fluids: physical evaluation of their potential for hyperthermia
Int J Hyperthermia
Cited by (106)
Oral liposomes encapsulating ginsenoside compound K for rheumatoid arthritis therapy
2023, International Journal of PharmaceuticsRecent advances of aggregation-induced emission nanoparticles (AIE-NPs) in biomedical applications
2022, Aggregation-Induced Emission (AIE): A Practical GuideDevelopment of mitochondrial targeted theranostic nanocarriers for treatment of gliomas
2021, Journal of Drug Delivery Science and TechnologyMultifunctional theranostic nanoparticles for biomedical cancer treatments - A comprehensive review
2021, Materials Science and Engineering CInvestigation of the magnetic behavior of the ferrites of alkali and alkaline earth metals for biomedical application
2019, Materials Today: ProceedingsBurgeoning tool of biomedical applications - Superparamagnetic nanoparticles
2018, Journal of Alloys and CompoundsCitation Excerpt :MTT assay results of Poly (D, L-lactic-co-glycolic acid) (PLGA)-SPION showed minimal cytotoxicity as synthesized by Lee et al. [74], with superparamagnetic behavior and saturation magnetization of 40.2 emu/g and 8.7 emu/g, respectively, for free SPIONs and PLGA- SPIONs. Prashant et al. [75] prepared superparamagnetic iron oxide-loaded poly (lactic acid)-d-α-Tocopherol 1000 succinate (TPGS) forming PLGA-TPGS-SPIONs. Cytotoxicity tests revealed that PLGA-TPGS-SPIONs had less toxicity on cancer cells at 10 mmol [Fe]/L, also the saturation magnetization decreased from 84.5emu/g to 79.23emu/g (at 15% emulsifier concentration).